Synthetic Biology: Immunotherapy by Design.
暂无分享,去创建一个
Wilson W Wong | W. Wong | Jang Hwan Cho | Matthew J Brenner | Nicole M L Wong | J. Cho | M. J. Brenner
[1] T. Wang,et al. Histidine decarboxylase (HDC)-expressing granulocytic myeloid cells induce and recruit Foxp3+ regulatory T cells in murine colon cancer , 2017, Oncoimmunology.
[2] Simon C Watkins,et al. The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. , 2016, Immunity.
[3] S. Rosenberg,et al. Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity , 2015, Journal of Virology.
[4] Wendell A. Lim,et al. Bacterial Virulence Proteins as Tools to Rewire Kinase Pathways in Yeast and Immune Cells , 2012, Nature.
[5] L. Bekker,et al. Adjunctive interferon-&ggr; immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial , 2012, AIDS.
[6] W. Meyer,et al. Robust polyfunctional T-helper 1 responses to multiple fungal antigens from a cell population generated using an environmental strain of Aspergillus fumigatus. , 2012, Cytotherapy.
[7] Kole T. Roybal,et al. Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors , 2016, Cell.
[8] Kole T. Roybal,et al. Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits , 2016, Cell.
[9] B. Spellberg,et al. Safety and efficacy of activated transfected killer cells for neutropenic fungal infections. , 2010, The Journal of infectious diseases.
[10] Tatsuo Fukagawa,et al. An auxin-based degron system for the rapid depletion of proteins in nonplant cells , 2009, Nature Methods.
[11] Navneeta Bansal,et al. Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies , 2012, Clinical Cancer Research.
[12] M. Petrou,et al. Exogenous Interferon‐γ Immunotherapy for Invasive Fungal Infections in Kidney Transplant Patients , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[13] C. Liu,et al. Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses , 2010, Clinical Cancer Research.
[14] A. Ohta,et al. A2A adenosine receptor protects tumors from antitumor T cells , 2006, Proceedings of the National Academy of Sciences.
[15] Kole T. Roybal,et al. Synthetic biology approaches to engineer T cells. , 2015, Current opinion in immunology.
[16] Y. Lévy,et al. CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses , 2017, Nature.
[17] A. Lanzavecchia,et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease , 2016, Science.
[18] Matthew L Baker,et al. TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy , 2013, Molecular therapy. Nucleic acids.
[19] M. Levings,et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. , 2016, The Journal of clinical investigation.
[20] Pamela A. Silver,et al. Engineering synthetic TAL effectors with orthogonal target sites , 2012, Nucleic acids research.
[21] Swapnil Bhatia,et al. A single-layer platform for Boolean logic and arithmetic through DNA excision in mammalian cells , 2017, Nature Biotechnology.
[22] R. Eils,et al. Engineering light-inducible nuclear localization signals for precise spatiotemporal control of protein dynamics in living cells , 2014, Nature Communications.
[23] D. Scott,et al. FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII. , 2017, Blood.
[24] A. Scheffold,et al. Clinical-scale isolation of the total Aspergillus fumigatus-reactive T-helper cell repertoire for adoptive transfer. , 2015, Cytotherapy.
[25] Kensaku Mori,et al. Advanced Endoscopic Navigation: Surgical Big Data, Methodology, and Applications. , 2018, Annual review of biomedical engineering.
[26] L. E. Strong,et al. Engineering Approaches to Study Cellular Decision Making. , 2018, Annual review of biomedical engineering.
[27] W. Wilson,et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.
[28] Qing He,et al. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.
[29] A. Pezeshki,et al. Naturally occurring p16Ink4a-positive cells shorten healthy lifespan , 2016, Nature.
[30] Christopher M. Vockley,et al. RNA-guided gene activation by CRISPR-Cas9-based transcription factors , 2013, Nature Methods.
[31] J. E. Brewer,et al. NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma , 2015, Nature Medicine.
[32] C. Gersbach,et al. A light-inducible CRISPR/Cas9 system for control of endogenous gene activation , 2015, Nature chemical biology.
[33] N. Mihaylova,et al. Selective silencing of DNA‐specific B lymphocytes delays lupus activity in MRL/lpr mice , 2007, European journal of immunology.
[34] J. Bonneterre,et al. Egfl7 promotes tumor escape from immunity by repressing endothelial cell activation. , 2011, Cancer research.
[35] L. Tsimring,et al. Entrainment of a Population of Synthetic Genetic Oscillators , 2011, Science.
[36] B. Ebert,et al. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3' enhancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[37] S. Gabriel,et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.
[38] J. Collins,et al. Construction of a genetic toggle switch in Escherichia coli , 2000, Nature.
[39] W. Lim,et al. The Principles of Engineering Immune Cells to Treat Cancer , 2017, Cell.
[40] E. Freireich,et al. Impact of high‐dose granulocyte transfusions in patients with cancer with candidemia , 2004, Cancer.
[41] B. Blazar,et al. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. , 2002, Blood.
[42] S. Gerber,et al. Optogenetic control of chemokine receptor signal and T-cell migration , 2014, Proceedings of the National Academy of Sciences.
[43] Christopher A. Voigt,et al. Genetic circuit design automation , 2016, Science.
[44] A. Zaas,et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease , 2009, Proceedings of the National Academy of Sciences.
[45] Timothy S. Ham,et al. Production of the antimalarial drug precursor artemisinic acid in engineered yeast , 2006, Nature.
[46] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[47] Russell M. Gordley,et al. Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors , 2016, Cell.
[48] L. Coussens,et al. Inflammation and Cancer , 2016 .
[49] D. Gottlieb,et al. Adoptive T-cell therapy for fungal infections in haematology patients , 2015, Clinical & translational immunology.
[50] L. Serrano,et al. Engineering stability in gene networks by autoregulation , 2000, Nature.
[51] M. Elowitz,et al. A synthetic oscillatory network of transcriptional regulators , 2000, Nature.
[52] Dana Carroll,et al. Enhancing Gene Targeting with Designed Zinc Finger Nucleases , 2003, Science.
[53] E. Yannaki,et al. Adoptive transfer of Aspergillus-specific T cells as a novel anti-fungal therapy for hematopoietic stem cell transplant recipients: Progress and challenges. , 2016, Critical reviews in oncology/hematology.
[54] Leonidas Bleris,et al. Biological 2-Input Decoder Circuit in Human Cells , 2014, ACS synthetic biology.
[55] C. Macken,et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[56] D. Powell,et al. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. , 2012, Cancer research.
[57] Yu Cao,et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies , 2016, Proceedings of the National Academy of Sciences.
[58] Jennifer Doudna,et al. RNA-programmed genome editing in human cells , 2013, eLife.
[59] F. Lienert,et al. Synthetic biology in mammalian cells: next generation research tools and therapeutics , 2014, Nature Reviews Molecular Cell Biology.
[60] C. Barbas,et al. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. , 2013, Trends in biotechnology.
[61] Alimuddin Zumla,et al. T-Cell Therapy: Options for Infectious Diseases , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[62] Stephen B Fox,et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] Morgan L. Maeder,et al. CRISPR RNA-guided activation of endogenous human genes , 2013, Nature Methods.
[64] M. Sadelain,et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[65] M. Horton,et al. Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor , 2012, Cancer Immunology, Immunotherapy.
[66] Seth M Steinberg,et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.
[67] Xiuyan Wang,et al. Clinical manufacturing of CAR T cells: foundation of a promising therapy , 2016, Molecular therapy oncolytics.
[68] S. Rosenberg,et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[69] H. Heslop,et al. Reversal of tumor immune inhibition using a chimeric cytokine receptor. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[70] Tyler Hill,et al. Inclusion of Strep-Tag II in design of antigen receptors for T cell immunotherapy , 2016, Nature Biotechnology.
[71] D. Clegg,et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells , 2017, Nature Biotechnology.
[72] D. Scott,et al. Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses. , 2015, Blood.
[73] Robert DeRose,et al. Rapid and orthogonal logic gating with a gibberellin-induced dimerization system. , 2012, Nature chemical biology.
[74] Nicolai J. Birkbak,et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.
[75] Zong-hai Li,et al. Clinical application and research progress on chimeric antigen receptor-modified T cells , 2016 .
[76] Karin Jirström,et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.
[77] S. Riddell,et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. , 2007, Human gene therapy.
[78] Ronnie J Winfrey,et al. Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification. , 2008, Molecular cell.
[79] S. Rosenberg,et al. Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy , 2012, Gene Therapy.
[80] Tobias Meyer,et al. An inducible translocation strategy to rapidly activate and inhibit small GTPase signaling pathways , 2005, Nature Methods.
[81] Jing Sun,et al. Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor , 2011, Clinical Cancer Research.
[82] Zachary N. Russ,et al. An enzyme-coupled biosensor enables (S)-reticuline production in yeast from glucose. , 2015, Nature chemical biology.
[83] G. Barnea,et al. The genetic design of signaling cascades to record receptor activation , 2008, Proceedings of the National Academy of Sciences.
[84] Gang Wang,et al. A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.
[85] E. V. Van Allen,et al. Genomic correlates of response to immune checkpoint blockade , 2019, Nature Medicine.
[86] James J. Collins,et al. Using Targeted Chromatin Regulators to Engineer Combinatorial and Spatial Transcriptional Regulation , 2014, Cell.
[87] T. Dull,et al. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. , 1994, Blood.
[88] Brian Kuhlman,et al. Engineering an improved light-induced dimer (iLID) for controlling the localization and activity of signaling proteins , 2014, Proceedings of the National Academy of Sciences.
[89] Zhen Xie,et al. Logic integration of mRNA signals by an RNAi-based molecular computer , 2010, Nucleic acids research.
[90] Wendell A. Lim,et al. Remote control of therapeutic T cells through a small molecule–gated chimeric receptor , 2015, Science.
[91] Michel Sadelain,et al. The basic principles of chimeric antigen receptor design. , 2013, Cancer discovery.
[92] Mithat Gönen,et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection , 2017, Nature.
[93] Tongguang Wang,et al. Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy , 2013, Journal of immunotherapy.
[94] Ernst Weber,et al. A Modular Cloning System for Standardized Assembly of Multigene Constructs , 2011, PloS one.
[95] A. Tosti,et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. , 2005, Blood.
[96] N. Sharpless,et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice , 2015, Nature Medicine.
[97] F. Bushman,et al. Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells , 2012, Science Translational Medicine.
[98] S. Rosenberg,et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.
[99] Sadik H. Kassim,et al. Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma , 2015, Clinical Cancer Research.
[100] S. Forman,et al. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. , 2012, Molecular immunology.
[101] Drew Endy,et al. Amplifying Genetic Logic Gates , 2013, Science.
[102] G. Drusano,et al. Dose Range Evaluation of Mycograb C28Y Variant, a Human Recombinant Antibody Fragment to Heat Shock Protein 90, in Combination with Amphotericin B-Desoxycholate for Treatment of Murine Systemic Candidiasis , 2011, Antimicrobial Agents and Chemotherapy.
[103] R. Schwendener,et al. Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. , 2009, Cancer research.
[104] E. Elinav,et al. Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. , 2009, Gastroenterology.
[105] S. Heilshorn,et al. Engineering Hydrogel Microenvironments to Recapitulate the Stem Cell Niche. , 2018, Annual review of biomedical engineering.
[106] Luke A. Gilbert,et al. Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression , 2013, Cell.
[107] A. Casadevall,et al. Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection. , 2010, The Journal of infectious diseases.
[108] Y. Kew,et al. Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[109] Timothy K Lu,et al. Synthetic circuits integrating logic and memory in living cells , 2013, Nature Biotechnology.
[110] Sang Yup Lee,et al. One-step fermentative production of poly(lactate-co-glycolate) from carbohydrates in Escherichia coli , 2016, Nature Biotechnology.
[111] Chan Hyuk Kim,et al. Versatile strategy for controlling the specificity and activity of engineered T cells , 2016, Proceedings of the National Academy of Sciences.
[112] Christopher A. Voigt,et al. Spatiotemporal Control of Cell Signalling Using A Light-Switchable Protein Interaction , 2009, Nature.
[113] B. Zoltowski,et al. Optimized second generation CRY2/CIB dimerizers and photoactivatable Cre recombinase , 2016, Nature chemical biology.
[114] J. Wess,et al. Engineering GPCR signaling pathways with RASSLs , 2008, Nature Methods.
[115] P. Emery,et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.
[116] C. Smolke,et al. Complete biosynthesis of opioids in yeast , 2015, Science.
[117] T. Harrison,et al. Immunotherapy for fungal infections. , 2012, Current opinion in microbiology.
[118] H. Heslop,et al. An inducible caspase 9 safety switch for T-cell therapy. , 2005, Blood.
[119] Keith E. J. Tyo,et al. Isoprenoid Pathway Optimization for Taxol Precursor Overproduction in Escherichia coli , 2010, Science.
[120] Joshua N Leonard,et al. Rewiring human cellular input-output using modular extracellular sensors. , 2017, Nature chemical biology.
[121] O. Yang,et al. HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies , 2016, Journal of Virology.
[122] Jeffry D. Sander,et al. Engineering Designer Transcription Activator‐‐Like Effector Nucleases (TALENs) by REAL or REAL‐Fast Assembly , 2012, Current protocols in molecular biology.
[123] Michel Sadelain,et al. PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses , 2013, Science Translational Medicine.
[124] T. Wandless,et al. Synthesis and analysis of stabilizing ligands for FKBP-derived destabilizing domains. , 2008, Bioorganic & Medicinal Chemistry Letters.
[125] S. Bhatia,et al. Ultrasensitive tumour-penetrating nanosensors of protease activity , 2017, Nature Biomedical Engineering.
[126] Ahmad S. Khalil,et al. A Synthetic Biology Framework for Programming Eukaryotic Transcription Functions , 2012, Cell.
[127] A. Scharenberg,et al. Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[128] M. Gossen,et al. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[129] A. Burgard,et al. Metabolic engineering of Escherichia coli for direct production of 1,4-butanediol. , 2011, Nature chemical biology.
[130] J. Liao,et al. Non-fermentative pathways for synthesis of branched-chain higher alcohols as biofuels , 2008, Nature.
[131] Adrian J. Thrasher,et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells , 2017, Science Translational Medicine.
[132] Michel Sadelain,et al. Therapeutic T cell engineering , 2017, Nature.
[133] Myles A Brown,et al. Lac repressor can regulate expression from a hybrid SV40 early promoter containing a lac operator in animal cells , 1987, Cell.
[134] Xu Zhang,et al. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy , 2016, Journal of Virology.
[135] Eugene S. Kim,et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytes , 2015, Nature Medicine.
[136] James Chappell,et al. Creating small transcription activating RNAs. , 2015, Nature chemical biology.
[137] E. Burchielli,et al. From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 22, 2013. For personal use only. , 2002 .
[138] Adrian P Gee,et al. Inducible apoptosis as a safety switch for adoptive cell therapy. , 2011, The New England journal of medicine.
[139] David D. Smith,et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. , 2006, Cancer research.
[140] C. C. Richardson,et al. Identification of Tetraspanin-7 as a Target of Autoantibodies in Type 1 Diabetes , 2016, Diabetes.
[141] O. Abudayyeh,et al. Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease , 2012, Nature Biotechnology.
[142] J. Roszik,et al. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection , 2014, Proceedings of the National Academy of Sciences.
[143] J. Stelling,et al. β-cell–mimetic designer cells provide closed-loop glycemic control , 2016, Science.
[144] Michael Z. Lin,et al. Tunable and reversible drug control of protein production via a self-excising degron , 2015, Nature chemical biology.
[145] R. Weiss,et al. A universal RNAi-based logic evaluator that operates in mammalian cells , 2007, Nature Biotechnology.
[146] R. Holt,et al. Cell-Based Therapeutics: Making a Faustian Pact with Biology. , 2017, Trends in molecular medicine.
[147] Ron Weiss,et al. Open-source, community-driven microfluidics with Metafluidics , 2017, Nature Biotechnology.
[148] A. Katakam,et al. Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity , 2009, Cancer Gene Therapy.
[149] D. Kontoyiannis,et al. The safety of interferon‐γ‐1b therapy for invasive fungal infections after hematopoietic stem cell transplantation , 2005 .
[150] D. G. Gibson,et al. Enzymatic assembly of DNA molecules up to several hundred kilobases , 2009, Nature Methods.
[151] J. Ito,et al. Epidemiology and treatment approaches in management of invasive fungal infections , 2011, Clinical epidemiology.
[152] Jens Boch,et al. Regulation of selected genome loci using de novo-engineered transcription activator-like effector (TALE)-type transcription factors , 2010, Proceedings of the National Academy of Sciences.
[153] J. Collins,et al. Toehold Switches: De-Novo-Designed Regulators of Gene Expression , 2014, Cell.
[154] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[155] Ai Leen Ang,et al. Treatment of severe neutropenic sepsis with granulocyte transfusion in the current era – experience from an adult haematology unit in Singapore , 2011, Transfusion medicine.